Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spare thousands from unnecessary cancer surgery

NCT ID NCT06040632

Knowledge-focused Sponsor: University of Aarhus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a blood test that detects tumor DNA can accurately identify patients who still have cancer after local removal of early-stage colorectal cancer. Currently, many patients undergo additional surgery even though about 85% are already cured by the initial procedure. If the blood test works, it could help doctors decide who truly needs more surgery and who can safely avoid it. The study involves 67 participants in Denmark.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
circulating tumor DNA (ctDNA) blood test
What this could lead to
If accurate, this blood test could help many patients avoid unnecessary follow-up surgery after early colorectal cancer removal.
What could go wrong
This is a small observational study (67 people) in Denmark, so results may not apply broadly. The test may not reliably detect all residual cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 67 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients having undergone local resection of pT1 colorectal cancer and with planned completion resection, as recommended by the local MDT board

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients having undergone local resection of pT1 colorectal cancer and with planned completion resection, as recommended by the local MDT board * The reason for the planning of completion resection may be non-micro radical tumor removal, piece-meal resection making assessment of resection margin impossible or the presence of one or more histological risk factors Exclusion Criteria: * Patients not able to understand information about the study and/or give informed consent * Patients not accepting blood samples stored in biobank * Cases with non-obtainable primary tumor tissue, required for the conduction of mutational analyses * Other recent (within 5 years) or current malignant disease, except basocellular carcinoma of the skin * Planned completion resection due to other factors, such as patient's wish or hereditary disposition for CRC, and with the absence of risk factors mentioned above * Withdrawal of consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm polyp of large intestine

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer Colorectal cancer stage I Colorectal polyp

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, North Denmark, 9000, Denmark

  • Aarhus University Hospital

    Aarhus, Central Jutland, 8000, Denmark

  • Bispebjerg Hospital

    Copenhagen, Capital Region of Denmark, 2400, Denmark

  • Gødstrup Hospital

    Herning, Central Jutland, 7400, Denmark

  • Herlev Hospital

    Herlev, Capital Region of Denmark, 2730, Denmark

  • Odense University Hospital

    Odense, The Region of Southern Denmark, 5000, Denmark

  • Regional Hospital Horsens

    Horsens, Central Jutland, 8700, Denmark

  • Regional Hospital Randers

    Randers, Central Jutland, 8930, Denmark

  • Regional Hospital Viborg

    Viborg, Central Jutland, 8800, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.